Evidence Hub

18F-FDG PET/CT Staging of Gastroesophageal Junction Adenocarcinoma With Skeletal Muscle Metastasis: A Case Report

David Gutiérrez-Albenda, A. M. Gutiérrez, Gabriel Infante, Mariana Parra, Ian Taylor

Cureus, 2026

Abstract

Malignancies of the upper digestive tract, including esophageal, gastroesophageal junction (GEJ), and gastric carcinoma, tend to present clinically with advanced pathologic staging. This has led to much debate regarding optimal imaging modalities for the purpose of disease staging. We present the case of a 54-year-old patient with a history of gastroesophageal reflux disease (GERD), who presented with a Siewert Type III GEJ adenocarcinoma with symptomatic skeletal muscle (SM) metastasis. On 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography with computed tomography (PET/CT), the patient was found to have multiple lymph nodes, bone, and SM metastases. This case report also provides a brief review of the current literature regarding 18F-FDG PET/CT use for esophageal and GEJ carcinoma pathologic staging.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free